Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 2(3)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07419334Phase 3Recruiting

Study of ALK-001 on the Progression of Stargardt Disease

Role: lead

NCT03845582Phase 2Completed

Phase 2/3 Study of ALK-001 in Geographic Atrophy

Role: lead

NCT02230228Phase 1Completed

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

Role: lead

NCT04239625Phase 2Active Not Recruiting

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Role: lead

NCT02402660Phase 2Enrolling By Invitation

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Role: lead

All 5 trials loaded